RATIONALE: Major Depressive Disorder (MDD) is a global public health burden, with traditional monoaminergic antidepressants facing critical limitations including slow onset, adverse side effects, and high rates of treatment resistance (TRD). Ketamine, a rapid-acting agent with sustained antidepressant effects, has revolutionized depression treatment paradigms but challenges conventional...
Purpose: To assess the pharmacokinetics and safety of pure S-ketamine (esketamine) in Chinese patients undergoing painless gastroscopy and evaluate the potential advantage of esketamine in clinical treatment compared with racemate ketamine hydrochloride injection. Patients and methods: A randomized, open-label, parallel-controlled, Phase I study was performed with 32 patients undergoing...